Analysts Set Integra LifeSciences Holdings Corporation (NASDAQ:IART) Price Target at $14.40

Integra LifeSciences Holdings Corporation (NASDAQ:IART) has earned a consensus recommendation of “Reduce” from the seven ratings firms that are currently covering the company, MarketBeat.com reports. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating on the company. The average twelve-month price target among brokers that have covered the stock in the last year is $14.40.

Several brokerages have recently issued reports on IART. Wall Street Zen lowered Integra LifeSciences from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. Wells Fargo & Company upgraded Integra LifeSciences to a “hold” rating in a research report on Wednesday, March 18th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Integra LifeSciences in a research note on Monday, December 29th. Finally, Citigroup decreased their price objective on Integra LifeSciences from $11.00 to $9.00 and set a “sell” rating for the company in a report on Wednesday, March 11th.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of IART. Allianz Asset Management GmbH grew its holdings in Integra LifeSciences by 88.7% in the third quarter. Allianz Asset Management GmbH now owns 433,738 shares of the life sciences company’s stock worth $6,215,000 after purchasing an additional 203,834 shares during the period. Hussman Strategic Advisors Inc. purchased a new position in shares of Integra LifeSciences during the third quarter valued at approximately $2,407,000. Systematic Financial Management LP lifted its holdings in shares of Integra LifeSciences by 12.8% during the second quarter. Systematic Financial Management LP now owns 1,056,920 shares of the life sciences company’s stock valued at $12,968,000 after purchasing an additional 120,086 shares during the last quarter. Edgestream Partners L.P. bought a new stake in shares of Integra LifeSciences in the 2nd quarter worth approximately $739,000. Finally, Sapience Investments LLC boosted its position in shares of Integra LifeSciences by 53.3% in the 2nd quarter. Sapience Investments LLC now owns 218,992 shares of the life sciences company’s stock worth $2,687,000 after purchasing an additional 76,170 shares in the last quarter. 84.78% of the stock is owned by hedge funds and other institutional investors.

Integra LifeSciences Stock Performance

NASDAQ:IART opened at $9.20 on Friday. The company has a 50-day moving average price of $10.67 and a 200-day moving average price of $12.43. The stock has a market cap of $717.05 million, a price-to-earnings ratio of -1.37 and a beta of 1.02. The company has a current ratio of 2.54, a quick ratio of 1.46 and a debt-to-equity ratio of 1.66. Integra LifeSciences has a 12 month low of $8.70 and a 12 month high of $22.27.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings results on Thursday, February 26th. The life sciences company reported $0.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.04. Integra LifeSciences had a negative net margin of 31.58% and a positive return on equity of 14.76%. The company had revenue of $434.93 million for the quarter, compared to analysts’ expectations of $429.62 million. During the same quarter in the previous year, the company earned $0.97 earnings per share. Integra LifeSciences’s quarterly revenue was down 1.7% on a year-over-year basis. Integra LifeSciences has set its Q1 2026 guidance at 0.370-0.450 EPS and its FY 2026 guidance at 2.300-2.400 EPS. Equities analysts predict that Integra LifeSciences will post 2.45 EPS for the current year.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.